mycoses	is a	fungal infection
mycoses	include	superficial infection
mycoses	include	cutaneous infection
mycoses	include	mucocutaneous infection
mycoses	include	subcutaneous infection
mycoses	include	systemic infection
Candida albicans	is a	fungal pathogen
Candida albicans	causes	mucocutaneous candidiasis
Aspergillus fumigatus	causes	invasive aspergillosis
Aspergillus fumigatus	is a	mold
Cryptococcus neoformans	causes	cryptococcal meningitis
Histoplasma capsulatum	causes	histoplasmosis
Coccidioides immitis	causes	coccidioidomycosis
Blastomyces dermatitidis	causes	blastomycosis
Pneumocystis jirovecii	causes	Pneumocystis pneumonia
Candida species	causes	candidemia
neutropenia	is a risk factor for	mycoses
HIV infection	is a risk factor for	cryptococcal meningitis
hematologic malignancy	is a risk factor for	invasive fungal infection
solid organ transplant	is a risk factor for	invasive fungal infection
diabetes mellitus	is a risk factor for	mucosal candidiasis
immunosuppression	is a risk factor for	invasive fungal infection
age	is a risk factor for	fungal infection
mycoses	diagnosed by	culture
mycoses	diagnosed by	tissue biopsy
KOH preparation	is used for	fungal detection
galactomannan assay	is a test for	invasive aspergillosis
beta-D-glucan assay	is a test for	fungal infection
PCR assay	detects	fungal DNA
blood culture	yields	fungal organism
CSF analysis	detects	cryptococcal antigen
CT scan	shows	nodular infiltrates
chest radiography	shows	cavitation
biopsy specimen	yields	histopathology
mycoses	treated with	antifungal agents
fluconazole	is a	azole antifungal
voriconazole	is a	azole antifungal
itraconazole	is a	azole antifungal
posaconazole	is a	azole antifungal
isavuconazole	is a	azole antifungal
amphotericin B	is a	polyene antifungal
liposomal amphotericin B	is a	liposomal formulation of amphotericin B
caspofungin	is a	echinocandin antifungal
anidulafungin	is a	echinocandin antifungal
micafungin	is a	echinocandin antifungal
candidemia	treated with	echinocandin
histoplasmosis	treated with	itraconazole
coccidioidomycosis	treated with	fluconazole
blastomycosis	treated with	itraconazole
pneumocystis pneumonia	treated with	TMP-SMX
cryptococcal meningitis	treated with	amphotericin B
cryptococcal meningitis	treated with	flucytosine
candidiasis	treated with	fluconazole
aspergillosis	treated with	voriconazole
aspergillosis	treated with	liposomal amphotericin B
amphotericin B	carries	nephrotoxicity
azole antifungals	cause	hepatotoxicity
drug interactions	occur with	azole antifungals
galactomannan assay	has	specificity
beta-D-glucan assay	has	sensitivity
invasive fungal infection	increases	mortality
invasive fungal infection	prolongs	hospital stay
neutropenia	prolongs	duration of fungemia
histoplasmosis	endemic in	Ohio and Mississippi valleys
coccidioidomycosis	endemic in	southwestern United States
histoplasmosis	presents with	pulmonary symptoms
pneumocystis pneumonia	presents with	dyspnea
cryptococcal meningitis	presents with	headache
candidiasis	presents with	mucosal lesions
lung involvement	occurs in	pulmonary aspergillosis
brain involvement	occurs in	cryptococcosis
immunocompromised status	predisposes to	mycoses
HIV infection	predisposes to	cryptococcosis
solid organ transplant recipient	predisposes to	invasive fungal infection
catheter-related infection	presents with	candidemia
beta-D-glucan	is a biomarker for	fungal infection
galactomannan index	correlates with	invasive aspergillosis severity
improvement	correlates with	antifungal therapy duration
length of stay	increases with	invasive fungal infection
mortality	increases with	delayed antifungal therapy
ICU admission	associated with	invasive fungal infection
pediatric patient	requires	adjusted antifungal dosing
Candida auris	is a	multidrug-resistant organism
Candida auris	causes	candidemia
intravenous catheter	associated with	candidemia
broad-spectrum antibiotics	predispose to	Candida overgrowth
nephrotoxicity	is an adverse effect of	amphotericin B
hepatic toxicity	is an adverse effect of	azole antifungals
liposomal formulation of amphotericin B	reduces	nephrotoxicity
echinocandins	have	activity against Candida
candida bloodstream infection	requires	source control
pneumocystis pneumonia	risk increased in	AIDS
TMP-SMX	used for	Pneumocystis pneumonia
endemic mycoses	occur in	geographic regions
mycoses	impact	healthcare costs
antifungal therapy	requires	careful dosing
treatment duration	depends on	organism and site
intravenous therapy	required for	severe fungal infections
oral therapy	used for	mild fungal infections
disseminated fungal infection	may require	surgical debridement
